{"id":3571,"date":"2023-02-27T15:19:01","date_gmt":"2023-02-27T14:19:01","guid":{"rendered":"https:\/\/www.access2meds.eu\/startside\/"},"modified":"2025-06-24T10:24:17","modified_gmt":"2025-06-24T08:24:17","slug":"startside","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/no\/","title":{"rendered":"Startside"},"content":{"rendered":"

[et_pb_section fb_built=»1″ admin_label=»Header» _builder_version=»4.20.2″ _module_preset=»default» background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg» background_position=»top_center» height=»100vh» max_height=»660px» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» custom_padding=»7px|30px||30px|false|true» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» header_font=»|700|||||||» header_line_height=»1.1em» custom_margin=»11px||||false|false» global_colors_info=»{}»]<\/p>\n

BEDRE TILGANG TIL <\/span>
INNOVATIVE HELSETEKNOLOGIER<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»first text blue pill» _builder_version=»4.20.0″ _module_preset=»default» background_enable_color=»off» custom_padding=»0px||0px||false|false» global_colors_info=»{}»][et_pb_row custom_padding_last_edited=»on|phone» module_class=»starttoppill» _builder_version=»4.20.2″ _module_preset=»default» background_color=»#3b3e84″ vertical_offset=»-90px» max_width=»1500px» module_alignment=»right» custom_margin=»||||false|false» custom_padding=»60px||50px|93px|false|false» custom_padding_tablet=»60px||50px|93px|false|false» custom_padding_phone=»|10px||65px|false|false» custom_css_main_element=»width:calc(100% – 125px)!important;» border_radii=»off|99999px|||99999px» global_colors_info=»{}» custom_css_main_element_last_edited=»on|phone» custom_css_main_element_phone=»width:calc(100%)!important;» custom_css_main_element_tablet=»width:calc(100% – 125px)!important;»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_font=»||||||||» text_text_color=»#FFFFFF» text_font_size=»24px» text_line_height=»1.33em» width=»100%» max_width=»825px» custom_margin_tablet=»» custom_margin_phone=»||0px||false|false» custom_margin_last_edited=»on|phone» custom_padding_tablet=»» custom_padding_phone=»||0px|10px|false|false» custom_padding_last_edited=»on|phone» text_font_size_tablet=»22px» text_font_size_phone=»16px» text_font_size_last_edited=»on|phone» text_line_height_tablet=»1.33em» text_line_height_phone=»1.2em» text_line_height_last_edited=»on|phone» global_colors_info=»{}»]<\/p>\n

ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) tar for seg behovet hos pasienter, leger, betalere, tilsynsmyndigheter og produsenter for \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) akseptable (rimelig forhold mellom helsegevinst og ressursbruk) og lettere tilgjengelig i Europa.<\/p>\n

[\/et_pb_text][et_pb_button button_url=»https:\/\/www.access2meds.eu\/no\/pavirkning\/» button_text=»Finn ut hvordan du kan dra nytte av det!» button_alignment=»right» module_class=»bubble-button» _builder_version=»4.20.2″ _module_preset=»default» custom_button=»on» button_text_size=»24px» button_text_color=»#FFFFFF» button_bg_color=»RGBA(255,255,255,0)» button_border_width=»0px» button_font=»||||||||» button_icon=»9||divi||400″ button_on_hover=»off» button_text_size_tablet=»24px» button_text_size_phone=»16px» button_text_size_last_edited=»on|phone» custom_css_main_element=»font-weight:500;» custom_css_after=»border-radius: 50%;background: #e85d6b;|| width: 30px;|| height: 30px;|| text-align: center; top:10px;|| line-height: 30px !important;» global_colors_info=»{}» custom_css_after_last_edited=»on|phone» custom_css_after_phone=»border-radius: 50%;background: #e85d6b;|| width: 20px;|| height: 20px;|| text-align: center; top:8px;|| line-height: 20px !important;» custom_css_after_tablet=»border-radius: 50%;background: #e85d6b;|| width: 30px;|| height: 30px;|| text-align: center; top:10px;|| line-height: 30px !important;»][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»faq» module_id=»ascertain-faq» _builder_version=»4.20.2″ _module_preset=»default» overflow-x=»hidden» custom_padding=»0px||0px||false|false» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» custom_padding=»0px|30px||30px|false|true» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_font=»|600|||||||» text_font_size=»36px» header_font=»|600|||||||» header_text_align=»left» header_text_color=»#FFFFFF» header_font_size=»36px» header_line_height=»75px» background_color=»#e85d6b» background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg» background_size=»custom» background_image_width=»31px» background_image_height=»30px» background_position=»center_right» background_horizontal_offset=»27px» width=»160px» height=»75px» height_tablet=»75px» height_phone=»50px» height_last_edited=»on|phone» custom_padding=»|86px|||false|false» link_option_url=»https:\/\/www.access2meds.eu\/faq\/» header_font_size_tablet=»36px» header_font_size_phone=»24px» header_line_height_tablet=»75px» header_line_height_phone=»50px» header_line_height_last_edited=»on|phone» custom_css_main_element=»overflow:visible;» custom_css_after=»content:%22%22; display:block; width:2000px; height:100%; background:#e85d6b; position:absolute; top:0;right:160px;» border_radii=»off||9999px|9999px|» global_colors_info=»{}»]<\/p>\n

FAQ<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» background_color=»#fbedec» positioning=»absolute» position_origin_a=»top_center» vertical_offset=»408px» max_width=»100%» height=»675px» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_2,1_2″ _builder_version=»4.20.0″ _module_preset=»default» custom_padding=»|30px|60px|30px|false|true» global_colors_info=»{}»][et_pb_column type=»1_2″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»Hva er ASCERTAIN?» image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-542576580_sturti-1024×683.jpg» image_icon_width=»100%» _builder_version=»4.20.2″ _module_preset=»4d864e31-c790-4706-8bfe-634bfca688dd» global_colors_info=»{}»]<\/p>\n

ASCERTAIN er et prosjekt som har som m\u00e5l \u00e5 hjelpe folk med \u00e5 f\u00e5 bedre tilgang til ny helseteknologi som medisiner, medisinsk utstyr og tester. Prosjektet utvikler et verkt\u00f8y som kan brukes av beslutningstakere for \u00e5 identifiserekostnadene ved og verdien av disse nye helseteknologiene. <\/p>\n

[\/et_pb_blurb][et_pb_blurb title=»Hva er ASCERTAIN policy-st\u00f8tteverkt\u00f8y?» image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1349268982-1024×683.jpg» image_icon_width=»100%» _builder_version=»4.20.2″ _module_preset=»4d864e31-c790-4706-8bfe-634bfca688dd» background_color=»#393C84″ custom_margin_tablet=»||0px||false|false» custom_margin_phone=»||0px||false|false» custom_margin_last_edited=»on|tablet» global_colors_info=»{}»]<\/p>\n

Verkt\u00f8yet vil v\u00e6re tilgjengelig for alle p\u00e5 internett, og det vil inneholde informasjon om kostnadene ved og verdien av disse nye helseteknologiene. Det vil ogs\u00e5 synliggj\u00f8re mulige milj\u00f8konsekvenser. Prosjektet vil samarbeide med pasienter, industrien, beslutningstakere og finansi\u00f8r for \u00e5 sikre at verkt\u00f8yet er av god kvalitet og nyttig. <\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=»1_2″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}» custom_css_main_element_last_edited=»on|tablet» custom_css_main_element_tablet=»margin-bottom:0 !important;» custom_css_main_element_phone=»margin-bottom:0 !important;»][et_pb_blurb title=»Hvorfor er det en utfordring \u00e5 prioritere innovativ helseteknologi?» image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1440000552-1024×683.jpg» _builder_version=»4.20.2″ _module_preset=»4d864e31-c790-4706-8bfe-634bfca688dd» background_color=»#E85D6B» custom_margin=»60px||30px||false|false» custom_margin_tablet=»0px||30px||false|false» custom_margin_phone=»0px||30px||false|false» custom_margin_last_edited=»on|tablet» global_colors_info=»{}»]<\/p>\n

Det er en utfordring for mange land i EU \u00e5 prioritere innf\u00f8ring av nye helseteknologier, fordi de ofte er kostbare og ikke alle har like god tilgang til dem. Dette verkt\u00f8yet vil hjelpe beslutningstakere med \u00e5 identifisere verdien av en teknologi (helsegevinst versus ressursbruk), hvilken merverdi den gir for pasientene, og hvilken innvirkning den kan ha p\u00e5 helsebudsjettet. <\/p>\n

[\/et_pb_blurb][et_pb_blurb title=»Hva er m\u00e5lene med ASCERTAIN?» image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1132274611_iStock_PeopleImages-1024×653.jpg» _builder_version=»4.20.2″ _module_preset=»4d864e31-c790-4706-8bfe-634bfca688dd» background_color=»#86B8BD» custom_margin=»||||false|false» global_colors_info=»{}»]<\/p>\n

M\u00e5let med ASCERTAIN er \u00e5 gj\u00f8re det enklere for folk \u00e5 forst\u00e5 kostnadene ved og verdien av nye helseteknologier. Verkt\u00f8yet vil v\u00e6re \u00e5pent for alle og vil kunne tilpasses ulike lands behov. Det vil inneholde informasjon om kostnadene og verdien av disse teknologiene, og det vil oppmuntre til \u00abgr\u00f8nnere\u00bb produksjon. <\/p>\n

[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ disabled_on=»on|on|off» module_id=»spr\u00e5k» _builder_version=»4.27.4″ _module_preset=»default» background_color=»rgba(134,184,189,0.3)» background_enable_image=»off» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n

VIL DU FORETREKKES \u00c5 LESE DENNE SIDEN P\u00c5 ET ANNEN SPR\u00c5K?<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_4,1_4,1_4,1_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Englisch-1.png» title_text=»Sprechblase_Engelsk» url=»https:\/\/www.access2meds.eu\/no\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Sprechblase_Nederlands.png» title_text=»Sprechblase_Nederlands» url=»https:\/\/www.access2meds.eu\/nl\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Deutsch.png» title_text=»Sprechblase_Deutsch» url=»https:\/\/www.access2meds.eu\/de\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_France.png» title_text=»Sprechblase_Frankrike» url=»https:\/\/www.access2meds.eu\/fr\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Romana.png» title_text=»Sprechblase_Romana» url=»https:\/\/www.access2meds.eu\/ro\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Sprechblase_Espanol.png» title_text=»Sprechblase_Espanol» url=»https:\/\/www.access2meds.eu\/es\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Norsk.png» title_text=»Sprechblase_Norsk» url=»https:\/\/www.access2meds.eu\/no\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Hrvatski.png» title_text=»Sprechblase_Hrvatski» url=»https:\/\/www.access2meds.eu\/hr\/» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»events» _builder_version=»4.27.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» custom_padding=»14px|30px|4px|30px|false|true» locked=»off» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.25.1″ _module_preset=»default» text_font=»|600|||||||» text_font_size=»36px» header_font=»|600||on|||||» header_text_align=»left» header_text_color=»#FFFFFF» header_font_size=»36px» header_line_height=»75px» background_color=»#393C84″ background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg» background_size=»custom» background_image_width=»31px» background_image_height=»30px» background_position=»center_right» background_horizontal_offset=»27px» width=»222px» height=»75px» height_tablet=»75px» height_phone=»50px» height_last_edited=»on|phone» custom_padding=»|60px|||false|false» link_option_url=»https:\/\/www.access2meds.eu\/no\/?page_id=3419#ascertain-events» header_font_size_tablet=»36px» header_font_size_phone=»24px» header_line_height_tablet=»75px» header_line_height_phone=»50px» header_line_height_last_edited=»on|phone» custom_css_main_element=»overflow:visible;» custom_css_after=»content:%22%22; display:block; width:2000px; height:100%; background:#393c84; position:absolute; top:0;right:222px;» border_radii=»off||9999px|9999px|» global_colors_info=»{}»]<\/p>\n

Events<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» max_width=»1170px» custom_padding=»0px|0px||0px|false|true» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_code _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»]

\r\n\t
\r\n\t
\r\n\t
\r\n\t\t\t
\r\n\t\t\t\t21
-
21<\/span>\r\n\t\t\t\tokt<\/span>\r\n\t\t\t<\/div>\r\n\t<\/div>\r\n\t\r\n\t
\r\n\t\t
\r\n\t\t\t\r\n\t\t\r\n\t\t

ASCERTAIN Final Conference<\/a><\/h3>\r\n\r\n\t\t
\r\n\t\t\t

Join us in Brussels for our final ASCERTAIN conference.<\/p>\n\r\n\t\t\t\r\n\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t

\r\n\t\t\t<\/a>\r\n\t\t\t\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\t<\/div>\r\n<\/div>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»partnerlogos» module_id=»ascertain-nyheter» _builder_version=»4.20.2″ _module_preset=»default» background_color=»#FFFFFF» custom_padding=»0px||0px||true|false» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» positioning=»absolute» position_origin_a=»top_center» custom_padding=»0px|30px|0px|30px|true|true» locked=»off» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.24.2″ _module_preset=»default» text_font=»|600|||||||» text_font_size=»36px» header_font=»|600|||||||» header_text_align=»left» header_text_color=»#FFFFFF» header_font_size=»36px» header_line_height=»75px» background_color=»#86B8BD» background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg» background_size=»custom» background_image_width=»31px» background_image_height=»30px» background_position=»center_right» background_horizontal_offset=»27px» width=»340px» width_tablet=»340px» width_phone=»250px» width_last_edited=»on|phone» height=»75px» height_tablet=»75px» height_phone=»50px» height_last_edited=»on|phone» custom_padding=»|86px|||false|false» link_option_url=»https:\/\/www.access2meds.eu\/no\/?page_id=3511″ header_font_size_tablet=»36px» header_font_size_phone=»24px» header_line_height_tablet=»75px» header_line_height_phone=»50px» header_line_height_last_edited=»on|phone» custom_css_main_element=»overflow:visible;» custom_css_after=»content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;» border_radii=»off||9999px|9999px|» global_colors_info=»{}»]<\/p>\n

VIDEO<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»news» module_id=»ascertain-nyheter» _builder_version=»4.20.2″ _module_preset=»default» background_color=»#E85D6B» custom_padding=»0px||0px||true|false» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.2″ _module_preset=»default» positioning=»absolute» position_origin_a=»top_center» z_index=»100″ custom_padding=»0px|30px|0px|30px|true|true» locked=»off» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_font=»|600|||||||» text_font_size=»36px» header_font=»|600||on|||||» header_text_align=»left» header_text_color=»#FFFFFF» header_font_size=»36px» header_line_height=»75px» background_color=»#048EA3″ background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg» background_size=»custom» background_image_width=»31px» background_image_height=»30px» background_position=»center_right» background_horizontal_offset=»27px» width=»190px» height=»75px» height_tablet=»75px» height_phone=»50px» height_last_edited=»on|phone» custom_padding=»|60px|||false|false» link_option_url=»https:\/\/www.access2meds.eu\/no\/?page_id=3419″ header_font_size_tablet=»36px» header_font_size_phone=»24px» header_line_height_tablet=»75px» header_line_height_phone=»50px» header_line_height_last_edited=»on|phone» custom_css_main_element=»overflow:visible;» custom_css_after=»content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;» border_radii=»off||9999px|9999px|» global_colors_info=»{}»]<\/p>\n

News<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» max_width=»100%» module_alignment=»center» custom_padding=»0px|0px|0px||true|false» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_dp_dmb_module_205 _builder_version=»4.20.0″ _module_preset=»default» custom_padding=»|||30px|false|false» global_colors_info=»{}»][\/et_pb_dp_dmb_module_205][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ _builder_version=»4.27.4″ _module_preset=»default» background_enable_color=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» header_2_font=»|600||on|||||» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» locked=»off» global_colors_info=»{}»]<\/p>\n

se videoene v\u00e5re for \u00e5 l\u00e6re mer om prosjektet<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/www.youtube.com\/watch?v=JjYDG7BDNDE» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

Oppdag hvordan serien \u00ab3 ting om\u00bb i seks deler ble til. I seks videoer tar vi sikte p\u00e5 \u00e5 gj\u00f8re komplekse problemstillinger mer tilgjengelige og skape en dypere forst\u00e5else av utfordringene og mulighetene som ligger i temaer relatert til ASCERTAIN. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/www.youtube.com\/watch?v=6ZtwscRvEls» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

«3 ting om verdien av nye kreftlegemidler» – Den sjette videoen i serien v\u00e5r! Denne videoen utforsker hvordan ulike interessenter definerer verdien av nye kreftlegemidler. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/youtu.be\/xMF2ddO9abM» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

«3 ting om kostnadseffektivitet» – Den femte videoen i serien v\u00e5r! Denne videoen tar for seg kostnadseffektivitetsanalyse – en viktig metode for \u00e5 vurdere om behandlinger gir god verdi. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/youtu.be\/e36OtJA90Qg» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

3 ting om refusjon» er den fjerde videoen i serien v\u00e5r. I denne videoen utforsker vi kompleksiteten i refusjon av legemidler – en n\u00f8kkelfaktor n\u00e5r det gjelder \u00e5 sikre pasientene tilgang til nye legemidler. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/www.youtube.com\/watch?v=6ZtwscRvEls» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

«3 ting om prising av nye legemidler» \u2013 Den tredje videoen i serien v\u00e5r! I denne videoen utforsker vi faktorene som p\u00e5virker prisingen av legemidler \u2013 et viktig tema n\u00e5r det gjelder prioritering avhelsetjenester. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/www.youtube.com\/watch?v=OlmiWOpy6IA&t=2s» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

«3 ting om differensierte priser» – Den andre videoen i serien v\u00e5r! I denne videoen g\u00e5r vi n\u00e6rmere inn p\u00e5 konseptet med differensierte priser – en strategi som brukes for \u00e5 fastsette ulike legemiddelpriser p\u00e5 tvers av land og pasientgrupper. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/youtu.be\/8NhuaohK_Qg» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.24.2″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

«3 ting om markedstilgang» – den f\u00f8rste videoen i serien v\u00e5r! I denne videoen dykker vi ned i det viktige konseptet markedstilgang – en viktig prosess for \u00e5 gj\u00f8re nye legemidler og behandlinger tilgjengelige for pasienter. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/www.youtube.com\/watch?v=fvjJ4-2nOxk» _builder_version=»4.24.2″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.24.2″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

Oppdag hvordan ASCERTAIN bekjemper ulikheter i tilgangen til helseteknologi med v\u00e5r nyeste animasjonsvideo! L\u00e6r mer om prosjektets m\u00e5l om \u00e5 gj\u00f8re helsetjenester akseptable (helsegevinster versus ressursbruk) og mer b\u00e6rekraftige, samtidig som vi fremmer innovasjon og tar hensyn til milj\u00f8konsekvenser. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.24.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_video src=»https:\/\/youtu.be\/sbPnTmX8Uxs» _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» global_colors_info=»{}»][\/et_pb_video][et_pb_text _builder_version=»4.27.4″ _module_preset=»default» max_width=»70%» module_alignment=»center» custom_margin=»||||false|false» custom_padding=»10px||10px||false|false» global_colors_info=»{}»]<\/p>\n

Vi er glade for \u00e5 kunne dele videoen v\u00e5r som viser lanseringen av ASCERTAIN-prosjektet i Rotterdam! Konsortiemedlemmene v\u00e5re var samlet for \u00e5 sparke i gang dette HORIZON-finansierte prosjektet. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ module_id=»kontakt» _builder_version=»4.20.2″ _module_preset=»default» background_color=»#86B8BD» custom_margin=»||||false|false» custom_padding=»16px||75px||false|false» box_shadow_style=»preset7″ box_shadow_horizontal=»0px» box_shadow_vertical=»-274px» box_shadow_color=»#FFFFFF» global_module=»910″ saved_tabs=»all» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» header_font=»Poppins semibold|||on|||||» header_font_size=»36px» custom_margin=»14px||23px||false|false» custom_margin_tablet=»» custom_margin_phone=»||30px||false|false» custom_margin_last_edited=»on|phone» header_font_size_phone=»24px» global_colors_info=»{}»]<\/p>\n

Kontakt<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_font=»Poppins regular||||||||» text_text_color=»#393C84″ text_font_size=»24px» text_line_height=»1.33em» module_alignment=»right» custom_margin=»||0px||false|false» text_font_size_tablet=»» text_font_size_phone=»18px» text_font_size_last_edited=»on|phone» global_colors_info=»{}»]<\/p>\n

Ta gjerne kontakt med oss hvis du har sp\u00f8rsm\u00e5l eller kommentarer! Vi svarer deg s\u00e5 snart som mulig. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ use_custom_gutter=»on» module_class=»tablet-three-cols» _builder_version=»4.20.2″ _module_preset=»default» max_width_tablet=»980px» max_width_phone=»500px» max_width_last_edited=»on|phone» custom_padding=»0px|30px|0px|30px|false|true» global_colors_info=»{}» custom_css_main_element_last_edited=»on|phone» custom_css_main_element_tablet=»display:flex;» custom_css_main_element_phone=»display:flex; flex-direction:column;»][et_pb_column type=»1_3″ _builder_version=»4.20.2″ _module_preset=»be0fba28-f74a-4ba0-9a8d-9cd30aca805d» global_colors_info=»{}» custom_css_main_element_last_edited=»on|tablet» custom_css_main_element_tablet=»margin-bottom:0;» custom_css_main_element_phone=»margin-bottom:20px;»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png» title_text=»Carin_Uyl-de-Groot» _builder_version=»4.20.2″ _module_preset=»a348f9e0-d57b-4c22-b522-c52b784fe57f» global_colors_info=»{}»][\/et_pb_image][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_text_color=»#FFFFFF» link_text_color=»#FFFFFF» global_colors_info=»{}»]<\/p>\n

For forskningsrelaterte sp\u00f8rsm\u00e5l:<\/p>\n

Carin Uyl-de Groot<\/strong>
Prosjektkoordinator<\/p>\n

Erasmus University Rotterdam
uyl@eshpm.eur.nl<\/a>
Telefon +31 10 4081583 +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.20.2″ _module_preset=»be0fba28-f74a-4ba0-9a8d-9cd30aca805d» background_color=»#393C84″ global_colors_info=»{}» custom_css_main_element_last_edited=»on|phone» custom_css_main_element_tablet=»margin-bottom:0;» custom_css_main_element_phone=»margin-bottom:20px;»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png» title_text=»Marcel-Langone» align=»center» _builder_version=»4.20.2″ _module_preset=»a348f9e0-d57b-4c22-b522-c52b784fe57f» global_colors_info=»{}»][\/et_pb_image][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_text_color=»#FFFFFF» link_text_color=»#FFFFFF» global_colors_info=»{}»]<\/p>\n

For generelle prosjektsp\u00f8rsm\u00e5l:<\/p>\n

Marcel Langone Marques<\/strong>
Prosjektleder<\/p>\n

Erasmus University Rotterdam
marcel.langonemarques@eur.nl<\/a>
Telefon +31 10 4081583 +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.20.2″ _module_preset=»be0fba28-f74a-4ba0-9a8d-9cd30aca805d» background_color=»#048EA3″ global_colors_info=»{}»][et_pb_image src=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png» title_text=»Mitt prosjekt-1 (7)» _builder_version=»4.21.0″ _module_preset=»a348f9e0-d57b-4c22-b522-c52b784fe57f» global_colors_info=»{}»][\/et_pb_image][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_text_color=»#FFFFFF» link_text_color=»#FFFFFF» global_colors_info=»{}»]<\/p>\n

For kommunikasjon:<\/p>\n

Lena Jessen<\/strong>
Prosjektleder<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
Telefon: +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»partnerlogos» module_id=»ascertain-nyheter» _builder_version=»4.20.2″ _module_preset=»default» background_color=»#FFFFFF» custom_padding=»0px||0px||true|false» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.20.0″ _module_preset=»default» positioning=»absolute» position_origin_a=»top_center» custom_padding=»0px|30px|0px|30px|true|true» locked=»off» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.20.2″ _module_preset=»default» text_font=»|600|||||||» text_font_size=»36px» header_font=»|600|||||||» header_text_align=»left» header_text_color=»#FFFFFF» header_font_size=»36px» header_line_height=»75px» background_color=»#048EA3″ background_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg» background_size=»custom» background_image_width=»31px» background_image_height=»30px» background_position=»center_right» background_horizontal_offset=»27px» width=»340px» width_tablet=»340px» width_phone=»250px» width_last_edited=»on|phone» height=»75px» height_tablet=»75px» height_phone=»50px» height_last_edited=»on|phone» custom_padding=»|86px|||false|false» link_option_url=»https:\/\/www.access2meds.eu\/no\/?page_id=3511″ header_font_size_tablet=»36px» header_font_size_phone=»24px» header_line_height_tablet=»75px» header_line_height_phone=»50px» header_line_height_last_edited=»on|phone» custom_css_main_element=»overflow:visible;» custom_css_after=»content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;» border_radii=»off||9999px|9999px|» global_colors_info=»{}»]<\/p>\n

Partner<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.20.2″ _module_preset=»default» module_alignment=»center» custom_padding=»90px|30px|0px|30px|false|true» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.20.0″ _module_preset=»default» global_colors_info=»{}»][et_pb_dp_oc_custom show_arrow=»off» show_control=»off» thumbnail_size=»medium_large» number_thumb=»4″ number_thumb_tablet=»4″ number_thumb_phone=»2″ number_thumb_last_edited=»on|phone» item_margin=»20″ _builder_version=»4.27.4″ _module_preset=»default» custom_padding=»30px||135px||false|false» hover_enabled=»0″ global_colors_info=»{}» sticky_enabled=»0″][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo-1.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/» admin_title=»CINO.IO» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/EUR-endorsement_01_RGB_2400_colour.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/» admin_title=»EUR» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo-1.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/» admin_title=»MP» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava-1.svg» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/» admin_title=»CUB» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/R.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/» admin_title=»UiO» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/» admin_title=»G\u00d6» _builder_version=»4.25.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/» admin_title=»EHA» _builder_version=»4.27.0″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24-1.png» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/» admin_title=»AIM» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=»https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg» url=»https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/» admin_title=»optimedis» _builder_version=»4.20.2″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_dp_oc_custom_item][\/et_pb_dp_oc_custom][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.<\/p>\n","protected":false},"author":1,"featured_media":2545,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3571","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nASCERTAIN - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER<\/title>\n<meta name=\"description\" content=\"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/no\/startside\/\" \/>\n<meta property=\"og:locale\" content=\"nb_NO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FASTSL\u00c5 - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER\" \/>\n<meta property=\"og:description\" content=\"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/no\/startside\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T08:24:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"FASTSL\u00c5 - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER\" \/>\n<meta name=\"twitter:description\" content=\"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Ansl. lesetid\" \/>\n\t<meta name=\"twitter:data1\" content=\"25 minutter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/\",\"name\":\"ASCERTAIN - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"datePublished\":\"2023-02-27T14:19:01+00:00\",\"dateModified\":\"2025-06-24T08:24:17+00:00\",\"description\":\"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/#breadcrumb\"},\"inLanguage\":\"nb-NO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"width\":1900,\"height\":1267},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/no\\\/startside\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Startside\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nb-NO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ASCERTAIN - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER","description":"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/no\/startside\/","og_locale":"nb_NO","og_type":"article","og_title":"FASTSL\u00c5 - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER","og_description":"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.","og_url":"https:\/\/www.access2meds.eu\/no\/startside\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T08:24:17+00:00","og_image":[{"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"FASTSL\u00c5 - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER","twitter_description":"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.","twitter_image":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Ansl. lesetid":"25 minutter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/no\/startside\/","url":"https:\/\/www.access2meds.eu\/no\/startside\/","name":"ASCERTAIN - BEDRE TILGANG TIL INNOVATIVE HELSETEKNOLOGIER","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/no\/startside\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/no\/startside\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","datePublished":"2023-02-27T14:19:01+00:00","dateModified":"2025-06-24T08:24:17+00:00","description":"ASCERTAIN er rettet mot pasienter, leger, betalere, tilsynsmyndigheter og produsenter som \u00f8nsker \u00e5 gj\u00f8re innovative helseteknologier (inkludert legemidler) rimeligere og mer tilgjengelige i Europa.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/no\/startside\/#breadcrumb"},"inLanguage":"nb-NO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/no\/startside\/"]}]},{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/www.access2meds.eu\/no\/startside\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","width":1900,"height":1267},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/no\/startside\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/no\/startside\/"},{"@type":"ListItem","position":2,"name":"Startside"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nb-NO"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/pages\/3571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/comments?post=3571"}],"version-history":[{"count":20,"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/pages\/3571\/revisions"}],"predecessor-version":[{"id":4541,"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/pages\/3571\/revisions\/4541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/media\/2545"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/no\/wp-json\/wp\/v2\/media?parent=3571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}